VG Health(VHT.US)

Hims & Hers: The company has decided to cease providing access to therapies. It will stop offering weight loss medications

2 Top Healthcare Stocks to Buy in February

The healthcare sector may rebound, presenting opportunities for investors. Two recommended stocks are Intuitive Surgical and Vertex Pharmaceuticals. Intuitive Surgical, despite facing challenges like high tariffs and competition, has a strong long-term outlook due to its leadership in robotic-assisted surgery. Vertex Pharmaceuticals is expanding its portfolio with new therapies for type 1 diabetes and kidney diseases, which could enhance its growth. Both stocks are considered attractive for buy-and-hold investors this February.

Top Picks 2026: AbbVie Inc.

AbbVie Inc. (ABBV), a biopharmaceutical company, has successfully transitioned from its reliance on the blockbuster drug Humira, which lost its patent in 2023. The company has launched new immunology drugs, Skyrizi and Rinvoq, which are projected to generate significant revenue, with combined sales of $6.9 billion in the last quarter. AbbVie has a robust pipeline with 20 drugs in phase III trials and over 50 in earlier stages. The stock has risen over 20% in 2025, and the company offers a dividend yield of 3.1%. Tom Hutchinson recommends purchasing AbbVie shares.

Merck & Co., Inc. (MRK): A bull case theory

A bullish thesis on Merck & Co., Inc. (MRK) was discussed on R. Dennis’s Substack by OppCost. As of January 28th, MRK shares were trading at $106.90, with trailing and forward P/E ratios of 14.28 and 17.27, respectively, according to Yahoo Finance.

Karyopharm Therapeutics (KPTI) Expected to Announce Earnings on Thursday

Karyopharm Therapeutics (NASDAQ: KPTI) is set to announce its Q4 2025 earnings on February 12, 2026, with expectations of a loss of $2.26 per share and revenue of $33.16 million. The stock recently traded up 2.8% to $6.26, with a market cap of $114.62 million. Analysts have mixed ratings, with Cantor Fitzgerald initiating coverage with an "overweight" rating, while Royal Bank of Canada lowered its price target. Institutional investors hold 66.44% of the stock, and Karyopharm focuses on developing drugs targeting the nuclear export protein XPO1.